Global Celiac Disease Drug research
Global Celiac Disease Drug research

Celiac Disease Drug Comprehensive Study by Application (First line of treatment, Second line of treatment) Players and Region - Global Market Outlook to 2024

Celiac Disease Drug Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Aug 2019 Edition 250 Pages 167 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Market Snapshot:
Celiac disease is an autoimmune disease in which the lining of the small intestine is damaged when gluten food is eaten. This disease can lead to various health problems such as miscarriage or infertility, intestinal cancer, seizures, gall bladder malfunction, neurological manifestation of the disease, stunted growth in children, and birth defects.

Market Trend
Research and Development in Healthcare Industry

Market Drivers
Increasing awareness about the healthcare Industry and Increase in Disposable Income among the population

Opportunities
Higher Consumption of Gluten-Containing Food and Ongoing Research on Celiac Disease Drug

The Players Covered in the Study are:
F. Hoffmann-La Roche (Switzerland), Johnson & Johnson (United States), Merck (United States), Pfizer (United States), ADMA Biologics (United States), Amgen (United States), Anthera Pharmaceuticals (United States), Bayer (Germany), Biogen (United States), BioLineRx (Israel) and Biotest (Germany)

Available Customization:
List of players that can be included in the study on immediate basis are Bristol-Myers Squibb (United States), Celgene (United States), Takeda Pharmaceutical (Japan), Novartis (Switzerland), LFB Group (United States) and Kedrion Biopharma (United States).

Report Objectives / Segmentation Covered
By Application
  • First line of treatment
  • Second line of treatment
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing awareness about the healthcare Industry
      • 3.2.2. Increase in Disposable Income among the population
    • 3.3. Market Challenges
      • 3.3.1. In Most Countries, Complex Regulation on These Drugs
    • 3.4. Market Trends
      • 3.4.1. Research and Development in Healthcare Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Celiac Disease Drug, by Application and Region (value and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Celiac Disease Drug (Value)
      • 5.2.1. Global Celiac Disease Drug by: Application (Value)
        • 5.2.1.1. First line of treatment
        • 5.2.1.2. Second line of treatment
      • 5.2.2. Global Celiac Disease Drug Region
        • 5.2.2.1. South America
          • 5.2.2.1.1. Brazil
          • 5.2.2.1.2. Argentina
          • 5.2.2.1.3. Rest of South America
        • 5.2.2.2. Asia Pacific
          • 5.2.2.2.1. China
          • 5.2.2.2.2. Japan
          • 5.2.2.2.3. India
          • 5.2.2.2.4. South Korea
          • 5.2.2.2.5. Taiwan
          • 5.2.2.2.6. Australia
          • 5.2.2.2.7. Rest of Asia-Pacific
        • 5.2.2.3. Europe
          • 5.2.2.3.1. Germany
          • 5.2.2.3.2. France
          • 5.2.2.3.3. Italy
          • 5.2.2.3.4. United Kingdom
          • 5.2.2.3.5. Netherlands
          • 5.2.2.3.6. Rest of Europe
        • 5.2.2.4. MEA
          • 5.2.2.4.1. Middle East
          • 5.2.2.4.2. Africa
        • 5.2.2.5. North America
          • 5.2.2.5.1. United States
          • 5.2.2.5.2. Canada
          • 5.2.2.5.3. Mexico
    • 5.3. Global Celiac Disease Drug (Price)
  • 6. Celiac Disease Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-La Roche (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. ADMA Biologics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Amgen (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Anthera Pharmaceuticals (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bayer (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Biogen (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. BioLineRx (Israel)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Biotest (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Celiac Disease Drug Sale, by Application and Region (value and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Celiac Disease Drug (Value)
      • 7.2.1. Global Celiac Disease Drug by: Application (Value)
        • 7.2.1.1. First line of treatment
        • 7.2.1.2. Second line of treatment
      • 7.2.2. Global Celiac Disease Drug Region
        • 7.2.2.1. South America
          • 7.2.2.1.1. Brazil
          • 7.2.2.1.2. Argentina
          • 7.2.2.1.3. Rest of South America
        • 7.2.2.2. Asia Pacific
          • 7.2.2.2.1. China
          • 7.2.2.2.2. Japan
          • 7.2.2.2.3. India
          • 7.2.2.2.4. South Korea
          • 7.2.2.2.5. Taiwan
          • 7.2.2.2.6. Australia
          • 7.2.2.2.7. Rest of Asia-Pacific
        • 7.2.2.3. Europe
          • 7.2.2.3.1. Germany
          • 7.2.2.3.2. France
          • 7.2.2.3.3. Italy
          • 7.2.2.3.4. United Kingdom
          • 7.2.2.3.5. Netherlands
          • 7.2.2.3.6. Rest of Europe
        • 7.2.2.4. MEA
          • 7.2.2.4.1. Middle East
          • 7.2.2.4.2. Africa
        • 7.2.2.5. North America
          • 7.2.2.5.1. United States
          • 7.2.2.5.2. Canada
          • 7.2.2.5.3. Mexico
    • 7.3. Global Celiac Disease Drug (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Celiac Disease Drug: by Application(USD Million)
  • Table 2. Celiac Disease Drug First line of treatment , by Region USD Million (2013-2018)
  • Table 3. Celiac Disease Drug Second line of treatment , by Region USD Million (2013-2018)
  • Table 4. South America Celiac Disease Drug, by Country USD Million (2013-2018)
  • Table 5. South America Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 6. Brazil Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 7. Argentina Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 8. Rest of South America Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 9. Asia Pacific Celiac Disease Drug, by Country USD Million (2013-2018)
  • Table 10. Asia Pacific Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 11. China Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 12. Japan Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 13. India Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 14. South Korea Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 15. Taiwan Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 16. Australia Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 17. Rest of Asia-Pacific Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 18. Europe Celiac Disease Drug, by Country USD Million (2013-2018)
  • Table 19. Europe Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 20. Germany Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 21. France Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 22. Italy Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 23. United Kingdom Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 24. Netherlands Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 25. Rest of Europe Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 26. MEA Celiac Disease Drug, by Country USD Million (2013-2018)
  • Table 27. MEA Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 28. Middle East Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 29. Africa Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 30. North America Celiac Disease Drug, by Country USD Million (2013-2018)
  • Table 31. North America Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 32. United States Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 33. Canada Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 34. Mexico Celiac Disease Drug, by Application USD Million (2013-2018)
  • Table 35. Company Basic Information, Sales Area and Its Competitors
  • Table 36. Company Basic Information, Sales Area and Its Competitors
  • Table 37. Company Basic Information, Sales Area and Its Competitors
  • Table 38. Company Basic Information, Sales Area and Its Competitors
  • Table 39. Company Basic Information, Sales Area and Its Competitors
  • Table 40. Company Basic Information, Sales Area and Its Competitors
  • Table 41. Company Basic Information, Sales Area and Its Competitors
  • Table 42. Company Basic Information, Sales Area and Its Competitors
  • Table 43. Company Basic Information, Sales Area and Its Competitors
  • Table 44. Company Basic Information, Sales Area and Its Competitors
  • Table 45. Company Basic Information, Sales Area and Its Competitors
  • Table 46. Celiac Disease Drug: by Application(USD Million)
  • Table 47. Celiac Disease Drug First line of treatment , by Region USD Million (2019-2024)
  • Table 48. Celiac Disease Drug Second line of treatment , by Region USD Million (2019-2024)
  • Table 49. South America Celiac Disease Drug, by Country USD Million (2019-2024)
  • Table 50. South America Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 51. Brazil Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 52. Argentina Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 53. Rest of South America Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 54. Asia Pacific Celiac Disease Drug, by Country USD Million (2019-2024)
  • Table 55. Asia Pacific Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 56. China Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 57. Japan Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 58. India Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 59. South Korea Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 60. Taiwan Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 61. Australia Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 62. Rest of Asia-Pacific Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 63. Europe Celiac Disease Drug, by Country USD Million (2019-2024)
  • Table 64. Europe Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 65. Germany Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 66. France Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 67. Italy Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 68. United Kingdom Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 69. Netherlands Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 70. Rest of Europe Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 71. MEA Celiac Disease Drug, by Country USD Million (2019-2024)
  • Table 72. MEA Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 73. Middle East Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 74. Africa Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 75. North America Celiac Disease Drug, by Country USD Million (2019-2024)
  • Table 76. North America Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 77. United States Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 78. Canada Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 79. Mexico Celiac Disease Drug, by Application USD Million (2019-2024)
  • Table 80. Research Programs/Design for This Report
  • Table 81. Key Data Information from Secondary Sources
  • Table 82. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Celiac Disease Drug: by Application USD Million (2013-2018)
  • Figure 5. South America Celiac Disease Drug Share (%), by Country
  • Figure 6. Asia Pacific Celiac Disease Drug Share (%), by Country
  • Figure 7. Europe Celiac Disease Drug Share (%), by Country
  • Figure 8. MEA Celiac Disease Drug Share (%), by Country
  • Figure 9. North America Celiac Disease Drug Share (%), by Country
  • Figure 10. Global Celiac Disease Drug share by Players 2018 (%)
  • Figure 11. Global Celiac Disease Drug share by Players (Top 3) 2018(%)
  • Figure 12. Global Celiac Disease Drug share by Players (Top 5) 2018(%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. F. Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 15. F. Hoffmann-La Roche (Switzerland) Revenue: by Geography 2018
  • Figure 16. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 17. Johnson & Johnson (United States) Revenue: by Geography 2018
  • Figure 18. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 19. Merck (United States) Revenue: by Geography 2018
  • Figure 20. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer (United States) Revenue: by Geography 2018
  • Figure 22. ADMA Biologics (United States) Revenue, Net Income and Gross profit
  • Figure 23. ADMA Biologics (United States) Revenue: by Geography 2018
  • Figure 24. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 25. Amgen (United States) Revenue: by Geography 2018
  • Figure 26. Anthera Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 27. Anthera Pharmaceuticals (United States) Revenue: by Geography 2018
  • Figure 28. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Bayer (Germany) Revenue: by Geography 2018
  • Figure 30. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 31. Biogen (United States) Revenue: by Geography 2018
  • Figure 32. BioLineRx (Israel) Revenue, Net Income and Gross profit
  • Figure 33. BioLineRx (Israel) Revenue: by Geography 2018
  • Figure 34. Biotest (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Biotest (Germany) Revenue: by Geography 2018
  • Figure 36. Global Celiac Disease Drug: by Application USD Million (2019-2024)
  • Figure 37. South America Celiac Disease Drug Share (%), by Country
  • Figure 38. Asia Pacific Celiac Disease Drug Share (%), by Country
  • Figure 39. Europe Celiac Disease Drug Share (%), by Country
  • Figure 40. MEA Celiac Disease Drug Share (%), by Country
  • Figure 41. North America Celiac Disease Drug Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • F. Hoffmann-La Roche (Switzerland)
  • Johnson & Johnson (United States)
  • Merck (United States)
  • Pfizer (United States)
  • ADMA Biologics (United States)
  • Amgen (United States)
  • Anthera Pharmaceuticals (United States)
  • Bayer (Germany)
  • Biogen (United States)
  • BioLineRx (Israel)
  • Biotest (Germany)
Additional players considered in the study are as follows:
Bristol-Myers Squibb (United States) , Celgene (United States) , Takeda Pharmaceutical (Japan) , Novartis (Switzerland) , LFB Group (United States) , Kedrion Biopharma (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation